Genentech, a successful biotechnology company, is set to present new pivotal data from its "extensive" hematology portfolio from December 11-14, 2021. This Annual Meeting and Exposition will feature over 90 abstracts from Genentech and 17 vocal showcasing of new immunotherapies, exclusive treatment combinations, novel endpoints and their applications, and some fixed-duration regimens.
Genentech will present 3 studies which include: "HAVEN 6 phase III interim data demonstrated Hemlibra’s favourable safety and efficacy profile in people with moderate or mild haemophilia A." Roche’s Chief Medical Officer and Head of Global Product Development, Levi Garraway, M.D., Ph.D., commented about Roche's approach to meeting the needs of patients with bleeding disorders: “Our data at ASH reinforce our conviction that following the science and developing versatile treatment approaches leads to improved outcomes for patients in increasingly meaningful ways.”
Genentech has co-developed HEMLIBRA with Chugai and Roche, who are all subsidiaries of Roche Holding AG.
Also Read - What is Hemlibra?
Want to learn more about bleeding disorders? Sign up for our newsletter here! SIGN UP
Comments